# Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

> **NCT00795548** · PHASE2 · COMPLETED · sponsor: **Heinrich-Heine University, Duesseldorf** · enrollment: 30 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** 5-Azacitidine

## Key facts

- **NCT ID:** NCT00795548
- **Lead sponsor:** Heinrich-Heine University, Duesseldorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-10
- **Final completion:** 2011-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00795548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00795548, "Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00795548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*